JSAM
VRTX icon

J. Safra Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

J. Safra Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.93K Hold
20
– – ﹤0.01% 383
2025
Q4 		$9.07K Hold
20
– – ﹤0.01% 368
2025
Q3 		$7.83K Buy
+20
New +$8.36K ﹤0.01% 280

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

J. Safra Asset Management's VRTX Position: Q1 2026 in Review

J. Safra Asset Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 20 shares worth $8.93K. The position accounts for ﹤0.01% of the portfolio, ranked #383.

J. Safra Asset Management first reported a position in VRTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $9.07K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • J. Safra Asset Management held 20 shares of Vertex Pharmaceuticals worth $8.93K as of Q1 2026.
  • J. Safra Asset Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of J. Safra Asset Management's portfolio in Q1 2026, its #383 holding.
  • J. Safra Asset Management first reported a position in Vertex Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • J. Safra Asset Management's Vertex Pharmaceuticals position peaked at $9.07K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on J. Safra Asset Management's 13F filing for Q1 2026, filed 4 May 2026.